Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Sales | 7,440,001 | 5,740,600 | 5,499,400 | 5,859,800 | 6,114,000 |
| Cost of Goods | 1,719,800 | 1,326,400 | 1,222,000 | 1,215,100 | 1,282,600 |
| Gross Profit | 5,720,200 | 4,414,200 | 4,277,400 | 4,644,700 | 4,831,401 |
| Operating Expenses | 3,728,898 | 3,136,300 | 3,080,600 | 3,054,000 | 3,431,799 |
| Operating Income | 1,992,102 | 1,278,300 | 1,196,800 | 1,590,800 | 1,400,200 |
| Other Income | 476,998 | 158,900 | 446,900 | 89,100 | 262,900 |
| Pre-tax Income | 2,469,100 | 1,437,200 | 1,643,700 | 1,679,900 | 1,663,100 |
| Income Tax | 352,300 | 228,800 | 231,700 | 223,400 | 167,400 |
| Net Income Continuous | 2,116,800 | 1,208,400 | 1,412,000 | 1,456,500 | 1,495,700 |
| Net Income | $2,116,800 | $1,208,400 | $1,412,000 | $1,456,500 | $1,495,701 |
| EPS Basic Total Ops | 2.33 | 1.33 | 1.56 | 1.60 | 1.79 |
| EPS Basic Continuous Ops | 2.33 | 1.33 | 1.56 | 1.60 | 1.60 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | 0.19 |
| EPS Diluted Total Ops | 2.31 | 1.33 | 1.55 | 1.60 | 1.77 |
| EPS Diluted Continuous Ops | 2.31 | 1.33 | 1.55 | 1.60 | 1.58 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | 0.19 |
| EBITDA(a) | $2,359,603 | $1,636,700 | $1,521,200 | $1,864,400 | $1,740,901 |